IDEXX Laboratories Inc $ 489.21 -3.65 (-0.74%)
Volume:
349,622
Avg Vol (1m):
375,046
Market Cap $:
41.73 Bil
Enterprise Value $:
42.55 Bil
P/E (TTM):
85.24
P/B:
94.71
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 0.18 | ||
Equity-to-Asset | 0.22 | ||
Debt-to-Equity | 2.25 | ||
Debt-to-EBITDA | 1.38 | ||
Interest Coverage | 19.12 | ||
Piotroski F-Score | 7 | ||
Altman Z-Score | 19.55 | ||
Beneish M-Score | -2.44 | ||
WACC vs ROIC |
Profitability Rank | 9/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | 24.12 | ||
Net Margin % | 19.2 | ||
ROE % | 207.09 | ||
ROA % | 26.24 | ||
ROC (Joel Greenblatt) % | 76.7 | ||
3-Year Revenue Growth Rate | 12.1 | ||
3-Year EBITDA Growth Rate | 15.5 | ||
3-Year EPS without NRI Growth Rate | 26.1 |
IDXX
Valuation Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
PE Ratio | 85.24 | ||
Forward PE Ratio | 74.61 | ||
PE Ratio without NRI | 85.24 | ||
Price-to-Owner-Earnings | 95.59 | ||
PB Ratio | 94.71 | ||
PS Ratio | 16.39 | ||
Price-to-Free-Cash-Flow | 95.27 | ||
Price-to-Operating-Cash-Flow | 72.61 | ||
EV-to-EBIT | 67.99 | ||
EV-to-EBITDA | 59.11 | ||
EV-to-Revenue | 16.44 | ||
PEG Ratio | 4.72 | ||
Shiller PE Ratio | 164.39 | ||
Current Ratio | 1.65 | ||
Quick Ratio | 1.24 | ||
Days Inventory | 70.35 | ||
Days Sales Outstanding | 47.55 | ||
Days Payable | 23.9 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | 1 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 279.55 | ||
Price-to-Intrinsic-Value-Projected-FCF | 9.63 | ||
Price-to-Intrinsic-Value-DCF (Earnings Based) | 3.9 | ||
Price-to-Median-PS-Value | 3.24 | ||
Price-to-Peter-Lynch-Fair-Value | 4.99 | ||
Price-to-Graham-Number | 32.57 | ||
Earnings Yield (Greenblatt) % | 1.48 | ||
Forward Rate of Return (Yacktman) % | 17.78 |